We’re improving your experience!

×

Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.

Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.

Stay tuned for these updates, and thank you for being part of our community!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02122770
Title Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Millennium Pharmaceuticals, Inc.
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Winship Cancer Institute at Emory University Atlanta Georgia 30322 United States Details
Siteman Cancer Center - South County Saint Louis Missouri 63110 United States Details
Sarah Cannon Cancer Center Nashville Tennessee 37203 United States Details
Mary Crowley Medical Research Center Dallas Texas 75230 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field